Screener
Xenon Pharmaceuticals XENE Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Xenon Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
FAQ
- What is Xenon Pharmaceuticals's debt-to-equity?
- Xenon Pharmaceuticals (XENE) reported debt-to-equity of 0× in Q2 2026.
- How has Xenon Pharmaceuticals's debt-to-equity changed year-over-year?
- Xenon Pharmaceuticals's debt-to-equity decreased by 62.0% year-over-year, from 0× to 0×.
- What is the long-term trend for Xenon Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's debt-to-equity has grown at a -6.6% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Xenon Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude